NEW YORK (GenomeWeb News) – Roche Molecular Systems and the German Cancer Research Center today announced they are collaborating on research to improve the ability to predict a woman's risk for developing cervical cancer.
The research is based on the German center's research into RNA markers and will be conducted on Roche's proprietary systems, including the cobas 4800 System.
Research by the center suggests that the relative amounts of specific spliced viral RNA molecules in human papillomavirus- infected cells can be used for the "highly accurate" discrimination of cervical cancer and high-grade from low-grade cervical lesions, Roche said in a statement. The center and Roche began collaborating in September and the work is expected to facilitate direct translation and application of relevant findings to the Roche diagnostics product line, the company added.
Terms of the deal were not disclosed.
"Our hope is that this will ultimately lead to the development of a new test to make cervical cancer screening, diagnosis, and grading even more accurate and specific," Paul Brown, president and CEO of Roche Molecular Diagnostics, said.
The company currently has the cobas 4800 HPV test, which tests for 12 high-risk HPV types. The test was launched in Europe last year but is not available in the US.